Guillain-Barré Syndrome Diagnostics: Ganglioside Antibody Determination IgG/IgM GM1, GM2, GM3, GD1a, GD1b, GT1b, GQ1b + Campylobacter jejuni Antibodies IgG/IgA
The comprehensive test detects antibodies to gangliosides and to the bacterium Campylobacter jejuni. Used for diagnosing Guillain-Barré syndrome and its variants, as well as for confirming autoimmune peripheral nerve damage after a past infection.
Profile composition:
Ganglioside antibodies IgG/IgM:
- GM1 — more often associated with the classic form of Guillain-Barré syndrome and motor neuropathy
- GM2 — may be detected in acute inflammatory polyneuropathies
- GM3 — found in autoimmune peripheral nerve damage
- GD1a — characteristic of acute motor axonal neuropathy (Guillain-Barré variant)
- GD1b — may be detected in sensory and ataxic disease forms
- GT1b — associated with severe polyneuropathy forms and cranial nerve damage
- GQ1b — characteristic of Miller-Fisher syndrome (Guillain-Barré variant with oculomotor nerve damage)
Campylobacter jejuni antibodies:
- IgG — indicate past infection, which may be a triggering factor for Guillain-Barré syndrome
- IgA — indicate recent or current intestinal infection associated with disease development risk
Biomaterial: Venous blood
- Submit fasting (8-12 hours without food)
- Avoid alcohol for 24 hours
- Avoid stress and physical exertion 30 minutes before
- If taking immunomodulators, hormonal, or anti-inflammatory medications — inform the doctor.
- increasing muscle weakness
- numbness, tingling in arms and legs
- gait disturbance
- decreased or absent tendon reflexes
- paralysis of unclear origin
- suspected Guillain-Barré syndrome
- after a past intestinal infection
Negative result — antibodies not detected.
Positive result:
ganglioside antibodies — confirm autoimmune peripheral nerve damageCampylobacter jejuni antibodies — indicate past infection associated with syndrome development
Important: the result is assessed only in combination with clinical symptoms and other tests.
